RlmN and Cfr are Radical SAM enzymes that modify a single adenosine nucleotide-A2503-in 23S ribosomal RNA. This nucleotide is positioned within the peptidyl transferase center of the ribosome, which is a target of numerous antibiotics. An unusual feature of these enzymes is their ability to carry out methylation of amidine carbons of the adenosine substrate. To gain insight into the mechanism of methylation catalyzed by RlmN and Cfr, deuterium labeling experiments were carried out. These experiments demonstrate that the newly introduced methyl group is assembled from an S-adenosyl-L-methionine (SAM)-derived methylene fragment and a hydrogen atom that had migrated from the substrate amidine carbon. Rather than activating the adenosine nucleotide of the substrate by hydrogen atom abstraction from an amidine carbon, the 5′-deoxyadenosyl radical abstracts hydrogen from the second equivalent of SAM to form the SAM-derived radical cation. This species, or its corresponding sulfur ylide, subsequently adds into the substrate, initiating hydride shift and S-adenosylhomocysteine elimination to complete the formation of the methyl group. These findings indicate that rather than acting as methyltransferases, RlmN and Cfr are methyl synthases. Together with the previously described 5′-deoxyadenosyl and 3-amino-3-carboxypropyl radicals, these findings demonstrate that all three carbon atoms attached to the sulfonium center in SAM can serve as precursors to carbon-derived radicals in enzymatic reactions.enzymatic methylation | RNA modification T o evade the action of antibiotics, pathogenic bacteria have evolved specific defense mechanisms, including modification of antibiotic targets (1). The recent identification of cfr, the chloramphenicol-florfenicol resistance gene in clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA), is a particularly severe example of bacterial resistance caused by target modification. The acquisition of this gene renders five important classes of antibiotics ineffective in treating infections (2, 3), including the entirely synthetic oxazolidinone antibiotic linezolid, an important therapeutic option and often the last line of defense in the treatment of infections caused by MRSA (4, 5). The drug resistance enzyme Cfr and its closely related homolog RlmN are enzymes that modify the 23S component of the ribosomal RNA (2, 3, 6, 7). The substrate of both enzymes is a single adenosine nucleotide-A2503-positioned within the catalytically crucial peptidyl transferase center of the ribosome, a common binding site of numerous antibiotics (8-10). RlmN and Cfr modify the substrate adenosine by adding methyl groups to C2 and C8 amidine carbons, respectively (Fig. 1). Commonly, RNA methylation is achieved by addition of substrate nucleophile (either a heteroatom or an enzyme-bound enolate) into the electrophylic methyl group of S-adenosyl-L-methionine (SAM) (11-13). By their reactivity and electronic demands, RlmN and Cfr substrate sites are distinct from other known methylation substrates in ...